Showing 2811-2820 of 5771 results for "".
- Alon Harris, MS, PhD, Named 2025 Recipient of Robert Ritch Award for Innovation and Excellence in Glaucomahttps://modernod.com/news/alon-harris-named-2025-recipient-of-robert-ritch-award-for-innovation-and-excellence-in-glaucoma/2482778/Alon Harris, MS, PhD, FARVO, has been announced as the 2025 recipient of The Glaucoma Foundation’s (TGF) 'Robert Ritch Award for Innovation and Excellence in Glaucoma.' The award, established in 2008 and named after TGF founder Robert Ritch, MD, honor
- Topcon Healthcare Acquires RetInSight to Accelerate AI-Powered Imaging in Eye Carehttps://modernod.com/news/topcon-healthcare-acquires-retinsight-to-accelerate-ai-powered-imaging-in-eye-care/2482777/Topcon Healthcare announced the acquisition of Vienna, Austria-based RetInSight. The move advances Topcon Healthcare’s vision of Healthcare from the Eye, enhancing access to intelligent diagnostics that increase access to high-quality eye care, reduce healthcare costs, and improve
- Oculis to Present Its Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/oculis-to-present-its-innovative-late-stage-pipeline-candidates-at-upcoming-ophthalmology-conferences/2482774/Oculis Holding AG announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Stud
- SpyGlass Pharma Presents 18-Month Data Demonstrating Improvements in Visual Acuity with IOL-Mounted Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-presents-18-month-data-demonstrating-improvements-in-visual-acuity-with-iol-mounted-drug-delivery-platform/2482772/SpyGlass Pharma announced that 18-month data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated improvements in both visual acuity and IOP outcomes, key objectives for long-term treatment of glaucoma or ocular hypertension. Th
- Heidelberg Engineering Showcases Technologies to Enhance the Future of Imaging Technology at ARVOhttps://modernod.com/news/heidelberg-engineering-showcases-technologies-to-enhance-the-future-of-imaging-technology-at-arvo/2482771/Heidelberg Engineering announced a portfolio of innovations aimed at redefining image quality, clinical research, and patient care in ophthalmology at ARVO. According to Heidelberg, Chameleon Imaging Research Platform is des
- datosX and Topcon Healthcare Forge Strategic Partnership to Accelerate Digital Health Innovationhttps://modernod.com/news/datosx-and-topcon-healthcare-forge-strategic-partnership-to-accelerate-digital-health-innovation/2482770/datosX Digital Health Labs, a provider of digital health technology (DHT) testing and real-world validation for DHTs, announced an investment and strategic partnership with Topcon Healthcare. Financial terms of the deal were not disclosed. </
- Nanoscope to Present New Data for Optogenetic Therapy for RP at Eyecelerator and ARVOhttps://modernod.com/news/nanoscope-to-present-new-data-for-optogenetic-therapy-for-rp-at-eyecelerator-and-arvo/2482769/Nanoscope Therapeutics announced participation at both the Eyecelerator and The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meetings. Nanoscope’s presentations will be centered around 126-week outcomes following treatment with its MCO-010
- FDA Expands Luminopia's Label to Include Patients 8 to 12 with Amblyopiahttps://modernod.com/news/fda-expands-luminopias-label-to-include-patients-8-to-12-with-amblyopia/2482768/Luminopia announced that the FDA has cleared its amblyopia treatment for patients aged 8 to 12 years, expanding its existing label from patients 4 to 7 years old with amblyopia associated with anisometropia and/or mild strabismus. The expanded label opens the door to a new treatment opt
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- Regeneron to Present 27 New Eylea HD Injection 8 mg Abstracts and Presentations at ARVOhttps://modernod.com/news/regeneron-to-present-27-new-eylea-hd-injection-8-mg-abstracts-and-presentations-at-arvo/2482766/Regeneron announced the upcoming presentation of 27 abstracts, including eight oral presentations on Eylea HD (aflibercept) Injection 8 mg in wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR). Among the new results and analyses are initia